Equities

Intellia Therapeutics Inc

Intellia Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)22.93
  • Today's Change0.41 / 1.82%
  • Shares traded1.61m
  • 1 Year change-33.28%
  • Beta1.7651
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 17-Sep-24
Select bar for recommendation details.
Recommendations17-Sep-24
Buy8
Outperform15
Hold6
Sell0
Strong Sell0

Share price forecast in USD

The 24 analysts offering 12 month price targets for Intellia Therapeutics Inc have a median target of 66.50, with a high estimate of 144.00 and a low estimate of 24.00. The median estimate represents a 190.01% increase from the last price of 22.93.
High528.0%144.00
Med190.0%66.50
Low4.7%24.00

Earnings history & estimates in USD

On Aug 08, 2024, Intellia Therapeutics Inc reported 2nd quarter 2024 losses of -1.52 per share.
The next earnings announcement is expected on Nov 07, 2024.
Average growth rate-4.20%
Intellia Therapeutics Inc reported annual 2023 losses of -5.42 per share on Feb 22, 2024.
Average growth rate-30.55%
More ▼

Revenue history & estimates in USD

Intellia Therapeutics, Inc. had 2nd quarter 2024 revenues of 6.96m. This missed the 19.16m consensus estimate of the 20 analysts following the company. This was 44.81% below the prior year's 2nd quarter results.
Average growth rate-43.87%
Intellia Therapeutics, Inc. had revenues for the full year 2023 of 36.28m. This was 30.40% below the prior year's results.
Average growth rate+4.71%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.